Neuland Laboratories
Niche, complex-chemistry specialist with a fast-scaling CMS (CDMO) franchise, including peptides; valued for innovator project pipeline and execution quality.
A full research profile for one company — what it does, how its financials have trended, how the market values it, and a balanced bull/bear/base investment memo.
Scan the top row for the headline numbers, read the charts for trends, check the three gauge scores, then read the auto-generated memo at the bottom. Sources for every figure are linked at the very bottom.
- EBITDA
- — Earnings before interest, tax, depreciation & amortisation — a proxy for operating cash profit.
- PAT
- — Profit After Tax — the bottom-line net profit.
- FCF
- — Free Cash Flow — cash left after running the business and capital spending.
- ANDA
- — Abbreviated New Drug Application — the US FDA filing to sell a generic drug.
Revenue
₹ crore · FY
EBITDA
₹ crore · FY
Margins
EBITDA & PAT margin %
R&D Spend
₹ crore · FY
Free Cash Flow
₹ crore · FY
Revenue Mix
By geography / segment
Quality Score
Growth Score
Regulatory Risk
Snapshot
Business Model
How the company makes money
Specialty/complex APIs + Custom Manufacturing Solutions (CMS) for innovators incl. peptides.
CMS project flow + peptide capacity
Lumpy project revenue & concentration
Peer Group
Click to compare
| Peer | Rev CAGR | EBITDA% | ROCE | P/E |
|---|---|---|---|---|
| Neuland Laboratories | 53% | 22% | 19% | 60x |
| Divi's Laboratories | 10% | 32% | 22% | 68x |
| Laurus Labs | 18% | 20% | 17.8% | 83x |
| Suven Pharmaceuticals (now Cohance Lifesciences) | -2% | 19% | 8.4% | 83x |
| Rubicon Research | 81% | 20.7% | 39.9% | 104x |
Investment Memo
Auto-generated from the data layer — illustrative, not advice
- • CMS project flow + peptide capacity underpins a 53% 5Y revenue CAGR.
- • Operating leverage as scale builds toward higher margins (currently 22% EBITDA).
- • Clean balance sheet (D/E 0.08) funds growth internally.
- • Lumpy project revenue & concentration.
- • Pricing/NLEM exposure on the domestic book can cap realisation.
- • Valuation at 60x P/E prices in continued execution — little margin for error.
Neuland Laboratories screens as a high-quality cdmo/crdmo franchise. With revenue of ₹1.5K Cr growing ~53% and 22% EBITDA margins, the base case is steady compounding driven by cms project flow + peptide capacity, while watching lumpy project revenue & concentration.
Trades at 60x P/E, 35.0x EV/EBITDA and 11.5x P/B. A premium to the sector — justified only if growth and returns hold.
- 1 India IPM outperformance & chronic mix
- 2 Gross-margin trajectory & new-launch contribution
- 3 R&D productivity (filings/approvals per ₹ of R&D)
- 4 Capital allocation — capex payback & M&A discipline
FY25 mix ~ GDS (generic API) 51% / CMS (CDMO) 49%. Revenue dipped slightly YoY on project lifecycle.